Efficacy of primary liver organoid culture from different stages of non-alcoholic steatohepatitis (NASH) mouse model
The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Non-alcoholic steatohepatitis (NASH) is associated with liver fibrosis and cirrhosis, which eventually leads to hepatocellular carcinoma. Although several animal models were developed to understand the mechanisms of NASH pathogenesis and progression, it remains obscure. A 3D organoid culture system can recapitulate organ structures and maintain gene expression profiles of original tissues. We therefore tried to generate liver organoids from different degrees [defined as mild (NASH A), moderate (NASH B) and severe (NASH C)] of methionine- and choline-deficient diet-induced NASH model mice and analyzed the difference of their architecture, cell components, organoid-forming efficacy, and gene expression profiles. Organoids from each stage of NASH model mice were successfully generated. Interestingly, epithelial-mesenchymal transition was observed in NASH C organoids. Expression of Collagen I and an activated hepatic stellite cell marker, α-sma was upregulated in the liver organoids from NASH B and C mice. The analysis of RNA sequencing revealed that several novel genes were upregulated in all NASH liver organoids. These results suggest that our generated liver organoids from different stages of NASH diseased mice might become a useful tool for in vitro studies of the molecular mechanism of NASH development and also for identifying novel biomarkers for early diagnosis of NASH disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Organogenesis in a dish: Modeling development and disease using organoid technologies
Lancaster, M. A., & Knoblich, J. A. (2014) · Science · doi:10.1126/science.1247125 · Cited by 2,931
Hepatic Stellate Cells: Protean, Multifunctional, and Enigmatic Cells of the Liver
Friedman, S. L. (2008) · Physiological Reviews · doi:10.1152/physrev.00013.2007 · Cited by 2,842
Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis
Tilg, H., & Moschen, A. R. (2010) · Hepatology · doi:10.1002/hep.24001 · Cited by 2,548
Dulai, P. S., Singh, S., Patel, J., Soni, M., Prokop, L. J., Younossi, Z., Sebastiani, G., Ekstedt, M., Hagstrom, H., Nasr, P., et al. (2017) · Hepatology · doi:10.1002/hep.29085 · Cited by 1,965
Long-Term Culture of Genome-Stable Bipotent Stem Cells from Adult Human Liver
Huch, M., Gehart, H., van Boxtel, R., Hamer, K., Blokzijl, F., Verstegen, M. M. A., Ellis, E., van Wenum, M., Fuchs, S. A., de Ligt, J., et al. (2015) · Cell · doi:10.1016/j.cell.2014.11.050 · Cited by 1,619
Broutier, L., Andersson-Rolf, A., Hindley, C. J., Boj, S. F., Clevers, H., Koo, B.-K., & Huch, M. (2016) · Nature Protocols · doi:10.1038/nprot.2016.097 · Cited by 834
Hepatic stellate cells in liver development, regeneration, and cancer
Yin, C., Evason, K. J., Asahina, K., & Stainier, D. Y. R. (2013) · Journal of Clinical Investigation · doi:10.1172/jci66369 · Cited by 719
Animal models of non‐alcoholic fatty liver disease: current perspectives and recent advances
Lau, J. K. C., Zhang, X., & Yu, J. (2017) · The Journal of Pathology · doi:10.1002/path.4829 · Cited by 373
Degrauwe, N., Suvà, M.-L., Janiszewska, M., Riggi, N., & Stamenkovic, I. (2016) · Genes & Development · doi:10.1101/gad.287540.116 · Cited by 324
Pathophysiology of NASH: perspectives for a targeted treatment
Marra, F., & Lotersztajn, S. (2013) · Current Pharmaceutical Design · doi:10.2174/13816128113199990344 · Cited by 163
Cited by
Mechanisms and disease consequences of nonalcoholic fatty liver disease
Loomba, R., Friedman, S. L., & Shulman, G. I. (2021) · Cell · doi:10.1016/j.cell.2021.04.015 · Cited by 2,002
“, 2020) primary liver organoids (Elbadawy et al., 2020), microtissues (Feaver et al.”
BackgroundEl-Husseiny, H. M., Mady, E. A., Hamabe, L., Abugomaa, A., Shimada, K., Yoshida, T., Tanaka, T., Yokoi, A., Elbadawy, M., & Tanaka, R. (2022) · Materials Today Bio · doi:10.1016/j.mtbio.2021.100186 · Cited by 533
Self-citationLuci, C., Bourinet, M., Leclère, P. S., Anty, R., & Gual, P. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.597648 · Cited by 195
In Vitro Models for Non-Alcoholic Fatty Liver Disease: Emerging Platforms and Their Applications
Ramos, M. J., Bandiera, L., Menolascina, F., & Fallowfield, J. A. (2022) · iScience · doi:10.1016/j.isci.2021.103549 · Cited by 127
Liver organoids: established tools for disease modeling and drug development
Sun, X.-C., Kong, D.-F., Zhao, J., Faber, K. N., Xia, Q., & He, K. (2023) · Hepatology Communications · doi:10.1097/hc9.0000000000000105 · Cited by 37
Metadata
- Authors
- Elbadawy, M., Yamanaka, M., Goto, Y., Hayashi, K., Tsunedomi, R., Hazama, S., Nagano, H., Yoshida, T., Shibutani, M., Ichikawa, R., Nakahara, J., Omatsu, T., Mizutani, T., Katayama, Y., Shinohara, Y., Abugomaa, A., Kaneda, M., Yamawaki, H., Usui, T., & Sasaki, K.
- Venue
- Biomaterials
- Publisher
- Elsevier BV
- Published
- 2020-04
- Volume
- 237
- Pages
- 119823
- ISSN
- 0142-9612 (ISSN-L)
- OpenAlex
- W3002015992
- Cited by
- 78
- References
- 13
- FWCI
- 7.68
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy of primary liver organoid culture from different stages of non-alcoholic steatohepatitis (NASH) mouse model. https://app.cochat.ai/papers/10.1016/j.biomaterials.2020.119823
- The paper
- Elbadawy, M., Yamanaka, M., Goto, Y., Hayashi, K., Tsunedomi, R., Hazama, S., Nagano, H., Yoshida, T., Shibutani, M., Ichikawa, R., Nakahara, J., Omatsu, T., Mizutani, T., Katayama, Y., Shinohara, Y., Abugomaa, A., Kaneda, M., Yamawaki, H., Usui, T., & Sasaki, K. (2020). Efficacy of primary liver organoid culture from different stages of non-alcoholic steatohepatitis (NASH) mouse model. Biomaterials. https://doi.org/10.1016/j.biomaterials.2020.119823
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.